Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 14/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12906161 | 0.72 | NOTUM (0.59) | NOTUMTSHRMAPTTLR8KDM4E | |
| SCHEMBL15173885 | 0.71 | HPGDS (0.33) | — | |
| SCHEMBL570272 | 0.71 | NOTUM (0.39) | NOTUMTSHR | |
| SCHEMBL13801151 | 0.70 | NOTUM (0.42) | NOTUMTSHRMAPTTLR8ALDH1A1 | |
| SCHEMBL21547878 | 0.68 | NOTUM (0.43) | NOTUMTSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL15174349 | 0.67 | PTK2 (0.39) | NOTUMLMNA | |
| SCHEMBL4766811 | 0.67 | FBP1 (0.31) | — | |
| SCHEMBL21539002 | 0.65 | NOTUM (0.44) | NOTUMTSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL21366093 | 0.65 | NOTUM (0.40) | NOTUMTSHRMAPTKDM4EALDH1A1 | |
| SCHEMBL25144924 | 0.64 | NOTUM (0.43) | NOTUMTSHRMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1711474-A1 | 5-PHENYPYRIDINES AND THEIR USE AS MICROBICIDES | Bayer CropScience Aktiengesellschaft (DE) | 2006-10-18 | — | — | EP | claimed |
| WO-2005070899-A1 | 5-PHENYLPYRIMIDINES AND THEIR USE AS MICROBICIDES | BAYER CROPSCIENCE AG (DE) | 2005-08-04 | — | — | WO | claimed |
| US-6613776-B2 | Protein serine/threonine kinase inhibitors used for treating diseases such as cancer, diabetes and Alzheimer's disease | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-02 | — | — | US | claimed |
| EP-3239139-B1 | CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE | NINGBO COMBIREG PHARMACEUTICAL TECH CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| EP-3239139-A1 | CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE | Shenzhen Salubris Pharmaceuticals Co., Ltd (CN) | 2017-11-01 | — | — | EP | disclosed |
| EP-2612857-B1 | CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE | SHENZHEN SALUBRIS PHARM CO LTD (CN) | 2017-07-26 | — | — | EP | disclosed |
| EP-1927594-A1 | 1,2,3-Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia | Arena Pharmaceuticals, Inc. (US) | 2008-06-04 | — | — | EP | disclosed |
| US-20070082874-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICLAS, INC. (US) | 2007-04-12 | — | — | US | disclosed |
| CN-1211253-A | Heterocyclyl-ergoline derivatives as 5-HT1A receptor ligands | PHARMACIA & UPJOHN SPA (IT) | 1999-03-17 | — | — | CN | disclosed |
| US-5491123-A | Herbicides containing 3-aminobenzo(B)thiophenes as antidotes | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082874-A1 | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, CYP4F3 | NOTUM 194/4885TSHR 1274/4885MAPT 4217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.